BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS
Status:
Recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
To assess the efficacy, and safety of BST-236 in patients unfit for intensive chemotherapy
with AML or HR MDS that failed or relapsed following first line therapy